Top Page
Beijing Tong Ren Tang Chinese Medicine Co
(OTC:3613)
Beijing Tong Ren Tang Chinese Medicine Co (3613) vs. iShares MSCI Hong Kong ETF (EWH)
Beijing Tong Ren Tang Chinese Medicine Co Business Overview & Revenue Model
Beijing Tong Ren Tang Chinese Medicine Co Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.61B | 1.52B | 1.73B | 1.56B | 1.32B |
| Gross Profit | 1.07B | 1.05B | 1.15B | 1.12B | 952.90M |
| EBITDA | 722.32M | 779.54M | 907.63M | 852.81M | 769.14M |
| Net Income | 500.28M | 540.39M | 645.88M | 607.84M | 542.46M |
Balance Sheet | |||||
| Total Assets | 4.56B | 4.43B | 4.23B | 3.83B | 3.42B |
| Cash, Cash Equivalents and Short-Term Investments | 1.82B | 2.38B | 2.24B | 2.28B | 1.85B |
| Total Debt | 123.42M | 131.81M | 103.08M | 128.48M | 106.01M |
| Total Liabilities | 313.09M | 413.75M | 486.49M | 295.48M | 287.46M |
| Stockholders Equity | 4.08B | 3.87B | 3.60B | 3.42B | 3.02B |
Cash Flow | |||||
| Free Cash Flow | -260.42M | 438.96M | 508.94M | 753.74M | 103.17M |
| Operating Cash Flow | -217.25M | 460.83M | 547.44M | 777.17M | 116.05M |
| Investing Cash Flow | 1.35B | -1.08B | 335.41M | -265.73M | 506.73M |
| Financing Cash Flow | -355.30M | -372.18M | -535.42M | -278.65M | -264.30M |
Beijing Tong Ren Tang Chinese Medicine Co Technical Analysis
Beijing Tong Ren Tang Chinese Medicine Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | HK$3.29B | 9.52 | 21.15% | 11.23% | 20.89% | 24.98% | |
74 Outperform | HK$6.25B | 6.87 | 11.61% | 9.30% | -18.09% | -15.08% | |
69 Neutral | $6.30B | 11.14 | 7.39% | 3.98% | 4.70% | -13.82% | |
68 Neutral | HK$7.40B | 14.79 | 12.58% | 3.96% | 5.69% | -7.43% | |
58 Neutral | $11.08B | 189.66 | 0.25% | 0.14% | -10.72% | -95.88% | |
55 Neutral | HK$6.96B | ― | -22.23% | ― | -14.17% | 76.00% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% |
Beijing Tong Ren Tang Chinese Medicine Co Corporate Events
Beijing Tong Ren Tang Chinese Medicine Co announced the successful passing of all proposed resolutions at its annual general meeting held on June 3, 2025. Key resolutions included the re-election of directors, approval of a final dividend, and the re-appointment of Ernst & Young as auditors, reflecting strong shareholder support and strategic continuity for the company.
Beijing Tong Ren Tang Chinese Medicine Co. has issued a supplemental notice for its upcoming annual general meeting on June 3, 2025. The notice includes additional resolutions for the re-election of Mr. Yue Zheng and Mr. Yan Han as executive directors. Shareholders are advised to submit a revised form of proxy to accommodate these new resolutions, ensuring their voting rights are maintained at the meeting.
Beijing Tong Ren Tang Chinese Medicine Co announced significant changes in its executive leadership, with the resignation of Mr. Chen Fei from multiple roles, including executive director and member of the competition executive committee, effective May 12, 2025. The company expressed gratitude for Mr. Chen’s contributions. Concurrently, Mr. Yue Zheng has been appointed as an executive director and vice chairman of the board, while Mr. Yan Han has taken on roles as an executive director, member of the competition executive committee, and authorized representative. These appointments are expected to influence the company’s strategic direction and reinforce its leadership structure.
Beijing Tong Ren Tang Chinese Medicine Co. has announced the postponement and rescheduling of its Annual General Meeting (AGM) to June 3, 2025, to allow more time for preparations. Consequently, the book closure periods for determining shareholder entitlements to attend the AGM and receive the final dividend for 2024 have been adjusted, impacting shareholders’ timelines for registration and dividend receipt.
Beijing Tong Ren Tang Chinese Medicine Co announced a postponement and rescheduling of its annual general meeting, which is set to approve a final dividend of HKD 0.35 per share for the year ended December 31, 2024. This update affects the book closure dates for determining dividend entitlement, with the new record date set for June 11, 2025, and payment scheduled for June 18, 2025. This announcement may impact shareholder expectations and the company’s financial planning.
Beijing Tong Ren Tang Chinese Medicine Company Limited has announced its Annual General Meeting scheduled for June 3, 2025, where key resolutions will be discussed. These include the adoption of financial statements, re-election of directors, approval of a final dividend of HK$0.35 per share, and the re-appointment of Ernst & Young as auditors. The meeting will also address the authorization for directors to manage share-related transactions, potentially impacting the company’s market operations and shareholder value.
Beijing Tong Ren Tang Chinese Medicine Co. announced the release of unaudited financial information for the first quarter of 2025 by its controlling shareholder, Tong Ren Tang Technologies Co. Ltd. This announcement is significant as it provides stakeholders with an early insight into the financial performance of the company and its subsidiaries, potentially impacting investor decisions and market positioning within the traditional Chinese medicine sector.
Beijing Tong Ren Tang Chinese Medicine Co. has entered into a strategic cooperation agreement with China Duty Free International Limited. This partnership aims to leverage both companies’ strengths to expand overseas markets, particularly in the Belt and Road and Southeast Asia regions. The collaboration will focus on expanding cooperation channels, developing exclusive product versions, and exploring innovative business models in Chinese health food and beverage. The agreement is effective for two years, with mechanisms for regular communication and coordination to ensure successful implementation.